Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States.
$4.62+2.90%
报价 2026-11-06
市值
$463.7M
EV
$200.4M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -42.7%
$1.84$8.06
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| STTKShattuck Labs, Inc. | $463.7M | +2.9% | +33.3% | -82% | – | – | – | |
| OVIDOvid Therapeutics Inc. | $556.6M | +10.5% | -97.0% | 100% | – | – | – | |
| ARTVArtiva Biotherapeutics, Inc. | $202.9M | +0.5% | -100.0% | 0% | – | – | – | |
| IFRXInflaRx N.V. | $192.3M | -3.7% | – | 48,201.6% | – | – | – | |
| STROSutro Biopharma, Inc. | $159.5M | +4.6% | -66.8% | 98.7% | – | – | – | |
| ZNTLZentalis Pharmaceuticals, Inc. | $122.4M | +0.6% | -22.2% | 0% | – | – | – | |
| KLRSKalaris Therapeutics Inc | $57.6M | +2.5% | -100.0% | 0% | – | – | – | |
| IMAImageneBio Inc | $46.6M | -1.4% | 0.0% | 0% | – | – | – | |
| CNTBConnect Biopharma Holdings Limited | $45.9M | -0.4% | – | 100% | – | – | – | |
| 同行中位数 | – | – | -81.9% | 49.4% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。
研究材料
电话会纪要摘要
暂无纪要摘要。